HUTCHMED (China) Limited American Depositary Shares
HCM
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Last trade$14.42
Day change-$0.31 (-2.10%)
Day range$14.31 – $14.76
Volume28,222
Market cap$2.56B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for HCM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for HCM.
Recent news
Company coverage with links to the original publishers.
HUTCHMED announced that the US FDA has granted Orphan Drug Designation to sovleplenib for treating autoimmune hemolytic anemia (AIHA), marking the second orphan designation for the drug following its recent designation for primary immune thrombocytopenia (ITP). The designation provides 7 years of US market exclusivity upon approval, along with other development incentives. NDAs for sovleplenib are currently under regulatory review in China for primary ITP and warm AIHA.
HUTCHMED announced that the US FDA has granted Orphan Drug Designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder. The designation provides 7 years of US market exclusivity upon approval, along with other development incentives. Sovleplenib is a novel, selective oral spleen tyrosine kinase inhibitor currently under regulatory review in China for ITP and warm antibody autoimmune hemolytic anemia.
HUTCHMED announced an expert webcast on November 5, 2026, to discuss Phase III clinical data for savolitinib in MET-driven NSCLC. The SANOVO study showed savolitinib plus TAGRISSO® reduced disease progression/death risk by 44% overall and 55% in high MET overexpression patients. The SAFFRON global Phase III trial demonstrated a 45% reduction in progression risk and 32% reduction in death risk in EGFR-mutated lung cancer after TAGRISSO® progression.
HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights (excluding Greater China and Taiwan) to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. HUTCHMED will receive $110 million upfront and up to $1.185 billion in milestone payments, plus tiered royalties. HUTCHMED remains responsible for global Phase I development.
HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.